Endpoint Blind Spots in Biotech
Biotech companies are built to move quickly. New research initiatives, distributed teams, outside collaborators, and accelerated timelines are part of the model. But that speed often creates a dangerous condition leadership rarely sees clearly: endpoints multiplying faster than security oversight. In many biotech firms, laptops, desktops, and remote systems operate with little to no unified […]